Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...

The move comes less than a year after the company attempted to save $1.5 billion through the layoff of some 2,200 employees.

Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...

We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks.

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...

Shares in Bristol-Myers Squibb traded lower after the drug maker gave 2025 guidance that undershot expectations. Bristol expects sales of about $45.5 billion in 2025, compared with the $46.3 billion ...

BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...

Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...